lilly glp 1 oral RO OFFERS ELI LILLY'S FOUNDAYO™, THE NEWEST GLP-1 INNOVATION GLP-1 Medication-Offering Health Platforms: Futurhealth

Future research is needed to study the use of obesity treatments other than AOM liraglutide and AOM semaglutide, including lifestyle interventions and use of other GLP-1 and non-GLP-1 anti-obesity medications

Consult with your thermal packaging provider if you want to learn more, ThermoSafe is happy to guide you

Patent Nos

Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones

PlexusDx serves all 50 states without insurance requirements, and all medications come from licensed 503A compounding pharmacies, ensuring quality and flexibility

Patients should monitor their response and adjust accordingly